Patents by Inventor Anand Natrajan
Anand Natrajan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220227711Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.Type: ApplicationFiled: April 7, 2022Publication date: July 21, 2022Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
-
Patent number: 11332445Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.Type: GrantFiled: February 26, 2020Date of Patent: May 17, 2022Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
-
Publication number: 20220073468Abstract: The present invention provides compounds used in the synthesis of chemiluminescent acridinium compounds and methods of producing these compounds. Specifically, methods are provided for the N-alkylation of acridan compounds using alkylating reagents. Typically, these alkylating reagents comprise a protected sulfonate group protected with an acid-labile protecting group.Type: ApplicationFiled: November 15, 2021Publication date: March 10, 2022Applicant: Siemens Healthcare Diagnostics Inc.Inventor: Anand Natrajan
-
Patent number: 11203573Abstract: The present invention provides compounds used in the synthesis of chemiluminescent acridinium compounds and methods of producing these compounds. Specifically, methods are provided for the N-alkylation of acridan compounds using alkylating reagents. Typically, these alkylating reagents comprise a protected sulfonate group protected with an acid-labile protecting group.Type: GrantFiled: June 25, 2019Date of Patent: December 21, 2021Assignee: Siemens Healthcare Diagnostics Inc.Inventor: Anand Natrajan
-
Publication number: 20210230119Abstract: The present invention provides compounds used in the synthesis of chemiluminescent acridinium compounds and methods of producing these compounds. Specifically, methods are provided for the N-alkylation of acridan compounds using alkylating reagents. Typically, these alkylating reagents comprise a protected sulfonate group protected with an acid-labile protecting group.Type: ApplicationFiled: June 25, 2019Publication date: July 29, 2021Applicant: Siemens Healthcare Diagnostics Inc.Inventor: Anand Natrajan
-
Patent number: 10859504Abstract: The present invention relates to methods of enhancing chemiluminescence from a chemiluminescent label comprising contacting a chemiluminescent label with an acid in the presence of a degradable cationic surfactant and hydrogen peroxide followed by the addition of a base. Related kits containing such degradable cationic surfactant are also provided. The degradable cationic surfactant can compress light emission time of the chemiluminescent label to an extent that is comparable to or shorter than conventional surfactants. The degradable cationic surfactant can also increase chemiluminescence of the chemiluminescent label, providing increased light emission output that is comparable to conventional surfactants.Type: GrantFiled: September 7, 2018Date of Patent: December 8, 2020Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Wen
-
Patent number: 10710962Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.Type: GrantFiled: May 28, 2016Date of Patent: July 14, 2020Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
-
Publication number: 20200190037Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.Type: ApplicationFiled: February 26, 2020Publication date: June 18, 2020Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
-
Publication number: 20190234883Abstract: The present invention relates to methods of enhancing chemiluminescence from a chemiluminescent label comprising contacting a chemiluminescent label with an acid in the presence of a degradable cationic surfactant and hydrogen peroxide followed by the addition of a base. Related kits containing such degradable cationic surfactant are also provided. The degradable cationic surfactant can compress light emission time of the chemiluminescent label to an extent that is comparable to or shorter than conventional surfactants. The degradable cationic surfactant can also increase chemiluminescence of the chemiluminescent label, providing increased light emission output that is comparable to conventional surfactants.Type: ApplicationFiled: September 7, 2018Publication date: August 1, 2019Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Wen
-
Patent number: 10073039Abstract: The present invention relates to methods of enhancing chemiluminescence from a chemiluminescent label comprising contacting a chemiluminescent label with an acid in the presence of a degradable cationic surfactant and hydrogen peroxide followed by the addition of a base. Related kits containing such degradable cationic surfactant are also provided. The degradable cationic surfactant can compress light emission time of the chemiluminescent label to an extent that is comparable to or shorter than conventional surfactants. The degradable cationic surfactant can also increase chemiluminescence of the chemiluminescent label, providing increased light emission output that is comparable to conventional surfactants.Type: GrantFiled: May 13, 2014Date of Patent: September 11, 2018Assignee: SIEMENS HEALTHCARE DIAGNOSTICS, INC.Inventors: Anand Natrajan, David Wen
-
Publication number: 20170320830Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.Type: ApplicationFiled: July 4, 2014Publication date: November 9, 2017Inventors: Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
-
Patent number: 9575062Abstract: Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity.Type: GrantFiled: June 11, 2014Date of Patent: February 21, 2017Assignee: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Anand Natrajan, David Sharpe, Qingping Jiang
-
Patent number: 9512080Abstract: A method is provided for N-alkylation of acridine compounds by reduction of acridines to corresponding acridans to improve the reactivity of the acridine nitrogen, and subsequent N-alkylation of the acridans in ionic liquid solvents to provide the corresponding acridinium compounds in high yield. This inventive process improves chemical conversion, and does not require the use of highly toxic alkylating agents, such as 1,3-propane sultone.Type: GrantFiled: July 10, 2013Date of Patent: December 6, 2016Assignee: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Anand Natrajan, David Wen
-
Patent number: 9487480Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.Type: GrantFiled: May 18, 2011Date of Patent: November 8, 2016Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
-
Publication number: 20160274094Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.Type: ApplicationFiled: May 28, 2016Publication date: September 22, 2016Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
-
Patent number: 9353056Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.Type: GrantFiled: May 18, 2011Date of Patent: May 31, 2016Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
-
Publication number: 20160131588Abstract: The present invention relates to methods of enhancing chemiluminescence from a chemiluminescent label comprising contacting a chemiluminescent label with an acid in the presence of a degradable cationic surfactant and hydrogen peroxide followed by the addition of a base. Related kits containing such degradable cationic surfactant are also provided. The degradable cationic surfactant can compress light emission time of the chemiluminescent label to an extent that is comparable to or shorter than conventional surfactants. The degradable cationic surfactant can also increase chemiluminescence of the chemiluminescent label, providing increased light emission output that is comparable to conventional surfactants.Type: ApplicationFiled: May 13, 2014Publication date: May 12, 2016Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Wen
-
Publication number: 20150197491Abstract: A method is provided for N-alkylation of acridine compounds by reduction of acridines to corresponding acridans to improve the reactivity of the acridine nitrogen, and subsequent N-alkylation of the acridans in ionic liquid solvents to provide the corresponding acridinium compounds in high yield. This inventive process improves chemical conversion, and does not require the use of highly toxic alkylating agents, such as 1,3-propane sultone.Type: ApplicationFiled: July 10, 2013Publication date: July 16, 2015Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Wen
-
Publication number: 20140295575Abstract: Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity.Type: ApplicationFiled: June 11, 2014Publication date: October 2, 2014Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Anand Natrajan, David Sharpe, Qingping Jiang
-
Patent number: 8778624Abstract: Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity.Type: GrantFiled: November 12, 2010Date of Patent: July 15, 2014Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Anand Natrajan, David Sharpe, Qingping Jiang